Overview
A research team led by Dr. Wang Yu from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences developed two systems, PRINCE and Little Prince, for dual small-molecule-controlled genome editing. These systems are designed to regulate CRISPR activity in living tissues, enabling its activation via specific drug inducers and maintaining it in a largely inactive state otherwise.
Research Context
The development addresses the control of therapeutic CRISPR editing, specifically focusing on achieving on-demand regulation. The systems represent an effort to implement small-molecule-based switches for genome editing applications.
Approach
The team developed PRINCE and Little Prince, which are characterized as dual small-molecule-controlled genome editing systems. These systems were designed with the specific function of being switchable by drug inducers. Their operational principle involves remaining largely silent in the absence of these inducers.
Findings
- The developed systems, PRINCE and Little Prince, function as dual small-molecule-controlled genome editing platforms.
- These systems demonstrated the ability to switch on CRISPR activity when drug inducers were present.
- In the absence of drug inducers, the CRISPR activity regulated by PRINCE and Little Prince remained largely silent.
Why This Matters
The described systems offer a mechanism for on-demand control over therapeutic CRISPR editing within living tissues. This controlled activation and silencing capability is pertinent for therapeutic applications of CRISPR technology.
Potential Applications
The research, as presented, points to the potential for therapeutic CRISPR editing to be controlled on-demand in living tissues. This suggests future applications where precise temporal regulation of gene editing is required.